Incyte Corporation (INCY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Group 1 - The new CEO of Incyte, William Meury, identified three key questions regarding the company's potential for growth and product flow, concluding that there is significant potential in marketed products and a pipeline of early and late-stage products [2] - Incyte operates in structurally attractive markets, particularly in oncology and immunology, which are considered to have strong growth prospects [3]